DESIGN, SYNTHESIS AND ANTIMICROBIAL STUDIES OF 5-BENZYLIDENE SUBSTITUTED RHODANINE CONTAINING HETEROCYCLES

CICI MATHEW; BINDU SARASWATI; NAND LAL; JOYAMMA VARKEY

doi:10.22159/ijpps.2021v13i5.40106

Authors

CICI MATHEW College of Pharmaceutical Sciences, Government Medical College, Thiruvananthapuram 695011 (India)
BINDU SARASWATI Corporate Research and Development Centre, HLL Lifecare Limited, Thiruvananthapuram 695017 (India)
NAND LAL Corporate Research and Development Centre, HLL Lifecare Limited, Thiruvananthapuram 695017 (India)
JOYAMMA VARKEY College of Pharmaceutical Sciences, Government Medical College, Thiruvananthapuram 695011 (India)

DOI:

https://doi.org/10.22159/ijpps.2021v13i5.40106

Keywords:

Anti-fungal, Rhodanine, Microdilution, Anti-bacterial

Abstract

Objective: The principal objective of the study was to synthesize and evaluate the biological activities of a novel class of 5-benzylidene substituted rhodanine derivatives as antimicrobial agents.

Methods: All the synthesized compounds (D1-D10) were screened for their antimicrobial activities using microdilution methods as per the reported procedure. All compounds were evaluated as potential antimicrobial agents against gram-positive bacteria: Bacillus cereus, Staphylococcus aureus, gram negative bacteria: Escherichia coli Pseudomonas aeruginosa and Klebsiella pneumoniae Fungal cultures used in the study were Aspergillus niger, Candida albicans, Candida parapsilosis, Candida tropicalis and Candida glabrata.

Results: Compound D6 showed good antifungal activity in the MIC range 16μg/ml against Candida tropicalis and Compound D10 showed good antifungal activity in the MIC range 16μg/ml against Candida glabrata. Compounds D2 and D5 showed good antibacterial activity at 32μg/ml. all the other compounds showed moderate antibacterial activity.

Conclusion: Based on the above results, it can be concluded that the compounds may lead to the development of more potent antimicrobial drug candidates in the near future.

Downloads

Download data is not yet available.

References

Khameneh B, Diab R, Ghazvini K. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb Pathog 2016;95:32-42.

Silveira AD, Perez A. Liposomes as novel anti-infectives targeting bacterial virulence factors? Expert Rev Anti Infect Ther 2015;13:531–3.

Song B, Wen S. Development of quorum-based anti-virulence therapeutics targeting gram-negative pathogens. Int J Mol Sci 2013;14:16570–99.

Cascioferro S, Cusimano MG, Schillaci D. Anti adhesion agents against gram-positive pathogens. Future Microbiol 2014;9:1209–20.

Rademacher J, Welte T. New antibiotics-standstill or progress. Med Klin Intensivmed Notfmed 2017;112:206–13.

Boucher HW, Talbot GH, Benjamin DK, Bradley J, Guidos RJ, Jones RN, et al. 10×20 progress-development of new drugs active against gram-negative bacilli: an update from the infectious diseases society of America. Clin Infectious Dis 2013;56:1685–94.

Mendgen T, Steuer C, Klein CD. Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem 2012;55:743–53.

Brown FC. 4-Thiazolidinones. Chem Rev 1961;61:463–521.

Tomasic T, Masic LP. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. Expert Opin Drug Discovery 2012;7:549–60.

Tomasic T, Masic LP. Rhodanine as a privileged scaffold in drug discovery. Cmc 2009;16:1596–629.

Tomasic T, Masic LP. Chemistry and reactivity of rhodanines. In: S Brase. Privileged scaffolds in medicinal chemistry: design, synthesis, evaluation. Cambridge: Royal Society of Chemistry; 2015. p. 214-31.

Singh SP, Parmar SS, Raman K, Stenberg VI. Chemistry and biological activity of thiazolidinones. Chem Rev 1981;81:175–203.

Hajibabaei K. 2-Thioxothiazolidin-4-one (Rhodanine). Synlett 2014;25:2083–4.

Pardasani R, Pardasani P, Sherry D, Chaturvedi V. Synthetic and antibacterial studies of rhodanine derivatives with indol-2, 3-diones. Ind J Chem-B 2001;40:1275–8.

Song MX, Zheng CJ, Deng XQ, Wang Q, Hou SP, Liu TT, et al. Deng, synthesis and bioactivity evaluation of rhodanine derivatives as potential anti-bacterial agents. Euro J Med Chem 2012;54:403–12.

Tejchman W, Korona Glowniak I, Malm A, Zylewski M, Suder P. Antibacterial properties of 5-substituted derivatives of rhodanine-3-carboxyalkyl acids. Med Chem Res 2017;26:1316–24.

Opperman TJ, Kwasny SM, Williams JD. Aryl rhodanines specifically inhibit staphylococcal and enterococcal biofilm formation. Antimicrob Agents Chemother 1995;53:4357–67.

Grant EB, Guiadeen D, Baum EZ, Foleno BD, Jin H, Montenegro DA, et al. The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors. Bioorg Med Chem Lett 2000;10:2179–82.

Miao J, Zheng CJ, Sun LP, Song MX, Xu LL, Piao HR. Synthesis and potential antibacterial activity of new rhodanine-3-acetic acid derivatives. Med Chem Res 2013;22:4125–32.

Inamori Y, Okamoto Y, Takegawa Y, Tsujibo H, Sakagami Y, Kumeda Y, et al. Insecticidal and antifungal activities of aminorhodanine derivatives. Biosci Biotechnol Biochem 1998;62:1025–7.

Marc G, Ionuţ I, Pirnau A, Vlase L. Microwave-assisted synthesis of 3,5-disubstituted thiazolidine-2,4-diones with antifungal activity. Design, synthesis, virtual and in vitro Antifungal Screening. Int J Farmacia 2017;65:414–22.

Xu H, Wang YY. Antifungal agents. Part 5:Synthesis and antifungal activities of aminoguanidine derivatives of N-arylsulfonyl-3-acylindoles. Bioorg Med Chem Lett 2010;20:7274–7.

Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I, et al. Effects of a new aldose reductase inhibitor on various tissues in vitro. J Pharmacol Exp Ther 1984;229:226–30.

Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007;50:1723–31.

Taniyama H, Yasui B, Takehara N, Uchida H. Chemotherapeutics for mycobacterium tuberculosis. XIX. Synthesis and antibacterial activity of some 3-substituted rhodanines. Yakugaku Zasshi 1959;79:1465–8.

Singh J, Nathan CF, Bryk R, Samy R, Pupek K, Gurney M. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis. WO Pat 2008005651; 2008. Available from: https://patents.google.com/ patent/ WO2008005651A2/en

Sim MM, Ng SB, Buss AD, Crasta SC, Goh KL, Lee SK. Benzylidene rhodanines as novel inhibitors of UDP-N-acetylmuramate/l-alanine ligase. Bioorg Med Chem Lett 2002;12:697–9.

Azizmohammadi M, Khoobi M, Ramazani A. 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur J Med Chem 2013;59:15–22.

Moorthy BT, Ravi S, Srivastava M, Chiruvella KK, Hemlal H, Joy O, et al. Novel rhodanine derivatives induce growth inhibition followed by apoptosis. Bioorg Med Chem Lett 2010;20:6297–301.

Katritzky AR, Tala SR, Lu H. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl) furans as HIV-1 entry inhibitors. J Med Chem 2009;52:7631–9.

He XY, Lu L, Qiu J, Zou P, Yu F, Jiang XK, et al. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene) methyl)-N-(3-carboxy-4-hydroxy) phenyl-2, 5-dimethylpyrroles and related derivatives targeting HIV-1 gp41. Bioorg Med Chem 2013;20:7539–48.

Damond F, Worobey M, Campa P, Farfara I, Colin G, Matheron S, Brun Vézinet F, et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses 2004;20:666–72.

Santiago ML, Range F, Keele BF, Li Y, Bailes E, Bibollet Ruche F, et al. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Tai Forest, Cote d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J Virol 2005;79:12515–27.

Keele BF, Van Heuverswyn F, Li Y. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006;313:523–6.

Taylor M, Alonso Gonzalez M, Gomez B, Korenromp E, Broutet N. World health organization global health sector strategy on sexually transmitted infections: an evidence-to-action summary for Colombia. Rev Colomb Obstet Ginecol 2017;68:193–201.

Tintori C, Corradi V, Magnani M, Manetti F, Botta M. Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. J Chem Inf Model 2008;48:2166–79.

Rinaldi M, Tintori C, Franchi L. A versatile and practical synthesis toward the development of novel HIV‐1 integrase inhibitors. Chem Med Chem 2011;6:343–52.

Botta L, Maccari G, Calandro P. One drug for two targets: biological evaluation of antiretroviral agents endowed with antiproliferative activity. Bioorg Med Chem Lett 2017;27:2502–5.

Zaveri M, Kawathekar N. Synthesis and antimalarial activity of some new 3-phenyl-2-thioxothiazolidin-4-one derivatives. Int J Curr Pharm Res 2017;9:58-61.

Bulic B, Pickhardt M, Khlistunova I. Rhodanine‐based tau aggregation inhibitors in cell models of tauopathy. Angew Chem 2007;119:9375–9.

Ono M, Hayashi S, Matsumura K. Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer’s brains. ACS Chem Neurosci 2011;2:269–75.

Mousavi SM, Zarei M, Hashemi SA, Babapoor A, Amani AM. A conceptual review of rhodanine: current applications of antiviral drugs, anticancer and antimicrobial activities. Artif Cells Nanomed Biotechnol 2019;47:1132-48.

Kaur Manjal S, Kaur R, Bhatia R. Synthetic and medicinal perspective of thiazolidinones: a review. Bioorg Chem 2017;75:406–23.

Xing C, Wang L, Tang X, Sham YY. Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1. Bioorg Med Chem Lett 2007;15:2167-76.

National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 2nd ed. Approved Standard M27-A2. Wayne, PA: NCCLS; 2002.

Clinical and Laboratory Standards Institute (CLSI), “Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard—ninth edition,” CLSI Documents M07-A9, Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, USA; 2012.

Ernst R, Roland NI, Gordon AA. Rhodanine. Org Synth 1947;27:73.

Tomasic T, Zidar N, Mueller Premru M, Kikelj D, Masic LP. Synthesis and antibacterial activity of 5-ylidenethiazolidin-4-ones and 5-benzylidene-4,6-pyrimidinediones. Eur J Med Chem 2010;45:1667–72.

Hardej N, Ashby CR Jr, Khadtare NS. The synthesis of phenylalanine-derived C5-substituted rhodanines and their activity against selected methicillin-resistant staphylococcus aureus (MRSA) strains. Eur J Med Chem 2010;45:5827–32.

Sortino M, Delgado P, Juarez S, Quiroga J, Abonia R, Insuasty B, et al. Synthesis and antifungal activity of (Z)-5-arylidenerhodanines. Bioorg Med Chem Lett 2007;15:484–94.